Regeneron in the news

Regeneron anticipates a $0.18 per share net income reduction in Q3 2026 due to R&D expenses.

Regeneron Pharmaceuticals Inc. stock outperformed competitors on a strong trading day.

Regeneron and Sanofi deepened their antibody collaboration with an expanded agreement, adding four new antibodies and involving significant upfront and potential milestone payments from Sanofi to Regeneron.

Regeneron Pharmaceuticals has been downgraded to 'Hold' as its stock is now considered appropriately priced, despite strong performance from DUPIXENT and EYLEA HD, but faces R&D setbacks.

Sanofi has deepened its 20-year drug development partnership with Regeneron, pledging up to $8 billion and focusing on new therapeutic programs building on the success of Dupixent.

Regeneron's muscle preserver drug was shown to be beneficial at lower doses during EASD 2026.

Regeneron is exploring combining its obesity drug with a lipid-lowering therapy to enter the competitive GLP-1 market.

Regeneron's drug trevogrumab halved muscle loss in a Phase II trial for obesity patients, leading to plans for further trials.

Regeneron's stock dropped after a new immunology alliance with Sanofi, which included a $1 billion upfront payment, did not improve terms for its key drug Dupixent, leading to investor disappointment.

Regeneron's experimental weight-loss drug, combined with Novo Nordisk's semaglutide, halved muscle loss in a study.

Regeneron and Sanofi expanded their antibody collaboration for next-generation inflammation and immunology therapies, involving a significant upfront payment and potential milestones for Regeneron.

Sanofi pays Regeneron $1 billion upfront and up to $7 billion in milestones for four early-stage immunology programs to replicate Dupixent's success and rebuild their partnership.

Regeneron Pharmaceuticals published a slide deck about an expanded collaboration on next-generation long-acting immunology antibodies.

Regeneron's investigational antibody helps obesity patients recover muscle mass lost after stopping GLP-1 therapy like Novo's Wegovy.

Sanofi and Regeneron expanded their global antibody collaboration, adding next-generation antibodies and building on the success of Dupixent.

Sanofi and Regeneron expanded their R&D alliance with an $8 billion pact for four new medicines, building on their successful collaboration history.

Sanofi and Regeneron expanded their alliance to develop next-generation immune system-regulating drugs, including four antibodies, with Regeneron leading R&D and receiving $1 billion upfront.

Sanofi paid Regeneron $1 billion upfront to renew their partnership, developing four next-generation antibodies for immune-mediated conditions as potential successors to Dupixent.

Regeneron Pharmaceuticals completed a Phase 1 clinical trial for ALN-F1202, an experimental drug designed to block Factor XII for blood clotting and inflammation.

Regeneron's experimental drug trevogrumab, when combined with Novo Nordisk's semaglutide, reduced muscle loss by 50% in obese patients during trials.